There has been an increased focus on making healthcare price information more transparent, but with only price information, patients and payers have no way to determine if paying a higher price is warranted.
There has been an increased focus on making healthcare price information more transparent, but with only price information, patients and payers have no way to determine if paying a higher price is warranted.
In an April 2016 Data Brief, “The Price-Quality Paradox in Health Care,” Eric Barrette and Kevin Kennedy of the Health Care Cost Institute (HCCI) concluded that the quality of healthcare services is largely unrelated to healthcare price.
The Data Brief found that patients and payers are limited in how they can use cost information without knowing what to expect for a given price. Price alone may not be sufficient for identifying quality, Barrette and Kennedy concluded. In some cases it appears that higher prices are actually associated with lower quality.
The HCCI Data Brief calculated quality of care measures with the same claims data used to estimate the average prices of common healthcare services that are publicly available. These measures are reported at the local, state, and national levels. The data set included deidentified HIPPA-compliant health insurance claims from multiple national health insurers, representing over 50 million covered lives. Membership and claims data included details such as zip codes, diagnostic codes, procedure codes, actual amounts paid by the insurer as well as copayments paid by the insured. Individual and employer-sponsored insurance claims were included in the analyses.
Quality and price of 5 measures are discussed in the brief: one related to asthma (asthma evaluation); 2 related to diabetes (diabetes evaluation and hemoglobin A1C test); and 2 related to hypertension (hypertension evaluation and creatinine test). The 5 state-level quality measures and their comparable price estimates were obtainable for 42 states and the District of Columbia.
The authors found the following:
“Although stakeholders need more information about the costs of health care services, they are limited in how they can use that information without knowing what to expect for a given price,” the authors wrote. “If policy makers and healthcare industry leaders expect transparency efforts to have real impacts on the healthcare system, making quality information more accessible and useable by stakeholders is also necessary.”
Survival Rates in CLL: Targeted Agents vs Fludarabine Combo Therapy Study
April 17th 2024Researchers conducted an analysis of 4 phase 3 trials, covering 2751 patients, to address the potential for targeted agents in younger and physically fit patients who have chronic lymphocytic leukemia (CLL).
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
Survival Rates in CLL: Targeted Agents vs Fludarabine Combo Therapy Study
April 17th 2024Researchers conducted an analysis of 4 phase 3 trials, covering 2751 patients, to address the potential for targeted agents in younger and physically fit patients who have chronic lymphocytic leukemia (CLL).
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
2 Commerce Drive
Cranbury, NJ 08512